|
Match
|
Document |
Document Title |
|
|
7390491 |
Agents comprising midkine or an inhibitor thereof as active ingredient
Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its...
|
|
|
7384634 |
Connective tissue growth factor
The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF and polynucleotides regulating CTGF expression. The invention also provides...
|
|
|
7371384 |
Compositions and methods of using angiopoietin-like 4 protein antibody
ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to...
|
|
|
7371383 |
Recombinant anti-interleukin-9 antibodies
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat...
|
|
|
7368111 |
Human antibodies specific for TGFβ2
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
|
|
|
7364736 |
Antibodies to OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
|
|
|
7364735 |
Method for diagnosis and treatment of haemophilia A patients with an inhibitor
A polynucleotide, comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity, or complementary to a nucleotide sequence coding for a human antibody for...
|
|
|
7364732 |
Method for treating inflammation
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
|
|
|
7361339 |
Methods for reducing morality associated with acute myocardial infarction
Methods of reducing mortality in myocardial infarction patients receiving a stent in connection with percutaneous transluminal coronary angioplasty include administering an anti-inflammatory...
|
|
|
7354585 |
Methods of treating coagulapathic or thrombotic disorders
The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention...
|
|
|
7354584 |
Recombinant IL-9 antibodies
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and...
|
|
|
7348002 |
Inducible ligand for α1β1 integrin and uses
The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.
|
|
|
7344716 |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
|
|
|
7342110 |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced...
|
|
|
7329737 |
Antibodies that bind hK-1
The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.
|
|
|
7318925 |
Methods of use for antibodies against parathyroid hormone
Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are...
|
|
|
7311913 |
Methods of treating thrombotic diseases with von Willebrand factor specific antibodies
Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
|
|
|
7304144 |
Antibodies binding to human TSLP Polypeptides
The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides,...
|
|
|
7297336 |
Factor IXa specific antibodies displaying factor VIIIa like activity
Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating...
|
|
|
7291333 |
Blockade of protein C activation reduces microvascular surgical blood loss
A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of...
|
|
|
7288250 |
Monoclonal antibodies against HMGB1
In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting...
|
|
|
7285269 |
Antibodies directed to tumor necrosis factor
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid...
|
|
|
7282206 |
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.
|
|
|
7279161 |
Factor IX/factor IXa activating antibodies and antibody derivatives
An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
|
|
|
7279158 |
Methods for the treatment of inflammatory joint disease
The use of compounds that block complement component C5 or its active fragments C5 a and/or C5 b (such compounds collectively referred to as “C5 blockers”) to treat established joint...
|
|
|
7279157 |
Method for treating psoriasis by administering an anti-il-12 antibody
The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods...
|
|
|
7276239 |
Recombinant A2-specific TNFα-specific antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7276238 |
Methods for using chemokine teck
Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods...
|
|
|
7273925 |
Methods and products for regulating lectin complement pathway associated complement activation
The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin...
|
|
|
7264803 |
Methods and pharmaceutical formulations for the treatment of pulmonary hypertension
A method of treating pulmonary hypertension in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to treat the pulmonary hypertension in...
|
|
|
7264801 |
EG-VEGF nucleic acids and polypeptides and method of use
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells...
|
|
|
7261894 |
Methods of treating inflammatory and/or autoimmune disease
The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such...
|
|
|
7261893 |
Neutralizing antibodies against GDF-8 and uses therefor
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in...
|
|
|
7261891 |
Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are...
|
|
|
7261890 |
Methods for using canine immunoglobulin variable domains and caninized antibodies
The present invention provides canine heavy chain and light chain (both λ and κ) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised...
|
|
|
RE39789 |
Tumor therapy
Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and...
|
|
|
7256273 |
Humanized antibodies that recognize beta amyloid peptide
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
|
|
|
7255854 |
Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly...
|
|
|
7252822 |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
The invention features methods and compositions for preventing or treating pain resulting from surgery or an incision by administering an antagonist of nerve growth factor (NGF). The NGF antagonist...
|
|
|
7250168 |
Tissue factor targeted thrombomodulin fusion proteins as anticoagulants
This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or...
|
|
|
7250165 |
Anti-TNF antibodies, compositions, methods and uses
The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or...
|
|
|
7247711 |
IL-23p40 specific antibody
Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived...
|
|
|
7247304 |
Methods of treating using anti-IL-15 antibodies
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced...
|
|
|
7244707 |
Regulation of cytotrophoblast cell differentiation and cell migration
The present invention is predicated on the discovery of certain interactions between cellular growth factors and opposing actions that control differentiation and migration or invasion of...
|
|
|
7238729 |
Silica mesoporous aerogels having three-dimensional nanoarchitecture with colloidal gold-protein superstructures nanoglued therein
This disclosure describes the first viable non-enzyme protein encapsulated within an aerogel. In this, a large excess of cyt c is added to a commercial buffered Au sol solution ( ) which results in...
|
|
|
7235239 |
Antibodies to a chemokine expressed in inflamed adenoid
The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for...
|
|
|
7226594 |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is...
|
|
|
7226593 |
Methods of treating cachexia with chimeric anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α(TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7223396 |
Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7223394 |
Human antibodies that bind human TNFα
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d...
|